Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center

American Journal of Cardiology

Volumn 95, Issue 6, 2005, Pages 716-721

  Gurm, Hitinder S ^a   Rajagopal, Vivek ^a   Fathi, Robert ^a   Vivekanathan, Deepak ^a   Yadav, Jay S ^a   Bhatt, Deepak L ^a   Ellis, Stephen G ^a   Lincoff, A Michael ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 14744305022     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.11.021     Document Type: Article

References (14)

1. The EPIC Investigation EPIC Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
2. The EPILOG Investigators EPILOG Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
3. The EPISTENT Investigators EPISTENT Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Lancet 352 1998 87 92
4. E.J. Topol, A.M. Lincoff, D.J. Kereiakes, N.S. Kleiman, E.A. Cohen, J.J. Ferguson, J.E. Tcheng, S. Sapp, R.M. Califf Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization Am J Med 113 2002 1 6
5. A.M. Lincoff, J.A. Bittl, R.A. Harrington, F. Feit, N.S. Kleiman, J.D. Jackman, I.J. Sarembock, D.J. Cohen, D. Spriggs, R. Ebrahimi Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
6. S.G. Ellis, V. Guetta, D. Miller, P.L. Whitlow, E.J. Topol Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: an analysis of results from 10,907 lesions and proposal for new classification scheme Circulation 100 1999 1971 1976
7. R.B. D'Agostino Jr Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
8. J. Hirsh Heparin N Engl J Med 324 1991 1565 1574
9. D.T. Eitzman, L. Chi, L. Saggin, R.S. Schwartz, B.R. Lucchesi, W.P. Fay Heparin neutralization by platelet-rich thrombi Role of platelet factor 4 Circulation 89 1994 1523 1529
10. Z. Xiao, P. Theroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256
11. J.I. Weitz, M. Hudoba, D. Massel, J. Maraganore, J. Hirsh Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Invest 86 1990 385 391
12. A. Aggarwal, B.E. Sobel, D.J. Schneider Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention J Thromb Thrombolysis 13 2002 161 165
13. J.I. Witting, P. Bourdon, D.V. Brezniak, J.M. Maraganore, J.W. Fenton II Thrombin-specific inhibition by and slow cleavage of hirulog-1 Biochem J 283 pt 3 1992 737 743
14. M.A. Parry, J.M. Maraganore, S.R. Stone Kinetic mechanism for the interaction of Hirulog with thrombin Biochemistry 33 1994 14807 14814